Skip to main content Accessibility help
  • Print publication year: 2013
  • Online publication date: June 2014


Related content

Powered by UNSILO

Suggested reading

Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004; 45(Suppl 6): 13–18.
Corrigan BW, Poole WF, Posvar EL, Strand JC, Alvey CW, Radulovic LL. Metabolic disposition of pregabalin in healthy volunteers. Clinical Pharmacology and Therapeutics 2001; 69: P18.
Elger CE, Brodie MJ, Anhut H, Lee CM, Barrett JA. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 2005; 46: 1926–1936.
Patsalos PN. Antiepileptic drug interactions: a clinical guide, 2nd edition. 2013, Springer, London, UK; 2013.
Randnitis EJ, Posver EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. Journal of Clinical Pharmacology 2003; 43: 277–283.
Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel α2-δ (alpha2 – delta) subunit as a target for antiepileptic drug discovery. Epilepsy Research 2007; 73: 137–150.